These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37839939)

  • 41. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
    Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
    Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
    Patel AA; Odenike O
    Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
    Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
    PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
    Tefferi A; Pardanani A; Gangat N
    Am J Hematol; 2024 Feb; 99(2):300-308. PubMed ID: 38164985
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of Ruxolitinib versus Best Available Therapy in Treating Primary Myelofibrosis.
    Hasan KM; Elmeshhadany AY; Shabila NP
    Sultan Qaboos Univ Med J; 2022 Aug; 22(3):393-399. PubMed ID: 36072080
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib.
    Kuykendall AT; Ball S; Mora B; Mo Q; Al Ali N; Maffioli M; Auteri G; Mazzoni C; Palumbo GA; Duminuco A; Longo A; Elli EM; Passamonti F; Palandri F; Komrokji R
    JCO Precis Oncol; 2024 Mar; 8():e2300593. PubMed ID: 38484210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of a symptom assessment in patients with myelofibrosis: qualitative study findings.
    Mesa RA; Su Y; Woolfson A; Prchal JT; Turnbull K; Jabbour E; Scherber R; Shields AL; Krohe M; Ojo F; Pompilus F; Cappelleri JC; Harrison C
    Health Qual Life Outcomes; 2019 Apr; 17(1):61. PubMed ID: 30975150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
    N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
    Kvasnicka HM; Thiele J; Bueso-Ramos CE; Sun W; Cortes J; Kantarjian HM; Verstovsek S
    J Hematol Oncol; 2018 Mar; 11(1):42. PubMed ID: 29544547
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
    Pemmaraju N; Garcia JS; Potluri J; Harb JG; Sun Y; Jung P; Qin QQ; Tantravahi SK; Verstovsek S; Harrison C
    Lancet Haematol; 2022 Jun; 9(6):e434-e444. PubMed ID: 35576960
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low-dose ruxolitinib shows effective in treating myelofibrosis.
    Yang Y; Luo H; Zheng Y; Zou Z; Niu T; Jia Y; Zhu H; Liu T; Wu Y; Chang H; Ji J; Li J; Pan L
    Ann Hematol; 2021 Jan; 100(1):135-141. PubMed ID: 33083863
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis.
    Palmer J; Mesa R
    Ther Adv Hematol; 2020; 11():2040620720925201. PubMed ID: 32477483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey.
    Soyer N; Ali R; Turgut M; Haznedaroğlu İC; Yılmaz F; Aydoğdu İ; Pir A; Karakuş V; Özgür G; Kiş C; Ceran F; İlhan G; Özkan M; Aslaner M; İnce İ; Yavaşoğlu İ; Gediz F; Sönmez M; Güvenç B; Özet G; Kaya E; Vural F; Şahin F; Töbü M; Durusoy R; Saydam G
    Turk J Med Sci; 2021 Jun; 51(3):1033-1042. PubMed ID: 33315343
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology].
    Tan YX; Luo J; Huang JX; Luo DM; Liang HY; Zhou X; Liu XL; Xu N
    Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):323-329. PubMed ID: 35680632
    [No Abstract]   [Full Text] [Related]  

  • 55. Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.
    Koschmieder S; Isfort S; Schulte C; Jacobasch L; Geer T; Reiser M; Koenigsmann M; Heinrich B; Wehmeyer J; von der Heyde E; Tesch H; Gröschl B; Bachhuber P; Großer S; Pahl HL
    Ann Hematol; 2023 Dec; 102(12):3383-3399. PubMed ID: 37792065
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
    Bewersdorf JP; Jaszczur SM; Afifi S; Zhao JC; Zeidan AM
    Cancer Manag Res; 2019; 11():10777-10790. PubMed ID: 31920387
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
    Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
    Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
    Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian JJ; Mesa R; Kuykendall AT; Vannucchi AM; Palandri F; Grosicki S; Devos T; Jourdan E; Wondergem MJ; Al-Ali HK; Buxhofer-Ausch V; Alvarez-Larrán A; Patriarca A; Kremyanskaya M; Mead AJ; Akhani S; Sheikine Y; Colak G; Mascarenhas J
    Future Oncol; 2022 Sep; 18(27):2987-2997. PubMed ID: 35950489
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 10
    Talpaz M; Prchal J; Afrin L; Arcasoy M; Hamburg S; Clark J; Kornacki D; Colucci P; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):336-346. PubMed ID: 34911667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice.
    Breccia M; Baratè C; Benevolo G; Bonifacio M; Elli EM; Guglielmelli P; Maffioli M; Malato A; Mendicino F; Palumbo GA; Pugliese N; Rossi E; Rumi E; Sant'Antonio E; Ricco A; Tiribelli M; Palandri F
    Ann Hematol; 2020 Jan; 99(1):65-72. PubMed ID: 31832751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.